Literature DB >> 30105644

Association Between Objectively Measured Physical Activity and Opioid, Hypnotic, or Anticholinergic Medication Use in Older People: Data from the Physical Activity Cohort Scotland Study.

Clare L Clarke1, Falko F Sniehotta2, Thenmalar Vadiveloo1, Peter T Donnan1, Miles D Witham3,4.   

Abstract

BACKGROUND: Centrally acting medications cause cognitive slowing and incoordination, which could reduce older people's physical activity levels. This association has not been studied previously.
OBJECTIVES: The aim of this study was to examine the association between opioid, hypnotic and anticholinergic medication, and objectively measured physical activity, in a cohort of older people.
METHODS: We used data from the Physical Activity Cohort Scotland, a representative cohort of community-dwelling older people aged 65 years and over who were assessed at baseline and again 2-3 years later. Objective physical activity was measured using Stayhealthy RT3 accelerometers over 7 days. Baseline medication use (opioid use, hypnotic use, modified Anticholinergic Risk Scale [mARS]) was obtained from linked, routinely collected community prescribing records. Cross-sectional and longitudinal associations between baseline medication use and both baseline activity and change in activity over time were analysed using unadjusted and adjusted linear regression models.
RESULTS: Overall, 310 participants were included in the analysis; mean age 77 years (standard deviation 7). No association was seen between baseline use of any medication class and baseline physical activity levels in unadjusted or adjusted models. For change in activity over time, there was no difference between users and non-users of hypnotics or opioids. Higher anticholinergic burden was associated with a steeper decline in activity over the follow-up period (mARS 0: - 7051 counts/24 h/year; mARS 1-2: - 15,942 counts/24 h/year; mARS ≥ 3: - 19,544 counts/24 h/year; p = 0.03) and this remained robust to multiple adjustments.
CONCLUSION: Anticholinergic burden is associated with greater decline in objectively measured physical activity over time in older people, a finding not seen with hypnotic or opioid use.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30105644     DOI: 10.1007/s40266-018-0578-7

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  28 in total

1.  Efficacy and cost of an exercise program for functionally impaired older patients with heart failure: a randomized controlled trial.

Authors:  Miles D Witham; Roberta L Fulton; Carol A Greig; Derek W Johnston; Chim C Lang; Marjon van der Pol; Dwayne Boyers; Allan D Struthers; Marion E T McMurdo
Journal:  Circ Heart Fail       Date:  2012-01-23       Impact factor: 8.790

2.  Simultaneous validation of ten physical activity questionnaires in older men: a doubly labeled water study.

Authors:  M Bonnefoy; S Normand; C Pachiaudi; J R Lacour; M Laville; T Kostka
Journal:  J Am Geriatr Soc       Date:  2001-01       Impact factor: 5.562

3.  Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients.

Authors:  Clare V Bostock; Roy L Soiza; Arduino A Mangoni
Journal:  Ther Adv Drug Saf       Date:  2013-12

4.  Comparative validity of physical activity measures in older adults.

Authors:  Lisa H Colbert; Charles E Matthews; Thomas C Havighurst; Kyungmann Kim; Dale A Schoeller
Journal:  Med Sci Sports Exerc       Date:  2011-05       Impact factor: 5.411

5.  The anticholinergic risk scale and anticholinergic adverse effects in older persons.

Authors:  James L Rudolph; Marci J Salow; Michael C Angelini; Regina E McGlinchey
Journal:  Arch Intern Med       Date:  2008-03-10

6.  Anticholinergic burden is associated with recurrent and injurious falls in older individuals.

Authors:  Anam Zia; S Kamaruzzaman; Phyo Kyaw Myint; M P Tan
Journal:  Maturitas       Date:  2015-10-23       Impact factor: 4.342

7.  Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.

Authors:  I-Min Lee; Eric J Shiroma; Felipe Lobelo; Pekka Puska; Steven N Blair; Peter T Katzmarzyk
Journal:  Lancet       Date:  2012-07-21       Impact factor: 79.321

8.  Barriers to physical activity in older adults in Germany: a cross-sectional study.

Authors:  Anna Moschny; Petra Platen; Renate Klaassen-Mielke; Ulrike Trampisch; Timo Hinrichs
Journal:  Int J Behav Nutr Phys Act       Date:  2011-11-02       Impact factor: 6.457

9.  "Keeping Moving": factors associated with sedentary behaviour among older people recruited to an exercise promotion trial in general practice.

Authors:  Ruth Heseltine; Dawn A Skelton; Denise Kendrick; Richard W Morris; Mark Griffin; Deborah Haworth; Tahir Masud; Steve Iliffe
Journal:  BMC Fam Pract       Date:  2015-05-28       Impact factor: 2.497

10.  Anticholinergic drugs and risk of dementia: case-control study.

Authors:  Kathryn Richardson; Chris Fox; Ian Maidment; Nicholas Steel; Yoon K Loke; Antony Arthur; Phyo K Myint; Carlota M Grossi; Katharina Mattishent; Kathleen Bennett; Noll L Campbell; Malaz Boustani; Louise Robinson; Carol Brayne; Fiona E Matthews; George M Savva
Journal:  BMJ       Date:  2018-04-25
View more
  3 in total

1.  Impact of Anticholinergic Medication Burden on Mobility and Falls in the Lifestyle Interventions for Elders (LIFE) Study.

Authors:  Patrick Squires; Marco Pahor; Todd M Manini; Scott Vouri; Joshua D Brown
Journal:  J Clin Med       Date:  2020-09-16       Impact factor: 4.241

Review 2.  Anticholinergic Drugs in Geriatric Psychopharmacology.

Authors:  Jorge López-Álvarez; Julia Sevilla-Llewellyn-Jones; Luis Agüera-Ortiz
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

Review 3.  Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review.

Authors:  Angela Lisibach; Valérie Benelli; Marco Giacomo Ceppi; Karin Waldner-Knogler; Chantal Csajka; Monika Lutters
Journal:  Eur J Clin Pharmacol       Date:  2020-10-03       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.